Jump to: Authorized Access | Attribution | Authorized Requests

Study Description

MSK SPECTRUM is a multi-modal, interdisciplinary prospective study of spatiotemporal determinants of high-grade serous ovarian cancer (HGSOC) evolution, treatment and response. Accounting for ~80% of ovarian cancers, HGSOC is the most lethal gynecological malignancy and is a cancer of major unmet clinical need. Challenges in disease management relate to several unresolved questions about disease biology and diagnostic modalities.

Prospective longitudinal collection of tissues and blood from laparoscopic biopsies and debulking surgeries enable multi-modal molecular measurements. The program brings together formidable expertise at Memorial Sloan Kettering Cancer Center (MSKCC) across the disciplines of high-resolution genomics and computer science, radiology and radiomics, surgery, tissue banking and sample preparation, medical oncology, immuno-oncology and high-resolution tissue profiling to generate a comprehensive and integrative dataset that will allow us to address the following major aims: i) characterize malignant and immune diversity at diagnosis, ii) survey the co-evolution of malignant cells and the immune response, and iii) stratify patients on standard-of-care and investigational compounds based on their genomic and transcriptomic signatures and changes to relevant genes (TP53, CCNE1, BRCA1/2, CDK12).

The goal is to create a framework to utilize integrated multi-modal data as a route to advanced diagnostics and to ultimately establish a proof-of-concept for integrated diagnostics.

Authorized Access
Publicly Available Data
Study Inclusion/Exclusion Criteria

Inclusion Criteria:

  • Newly diagnosed patients with confirmed pathological diagnosis of high-grade serous ovarian cancer
  • Patients were treatment-naive and stage III/IV.
Study History
  • January 2019 - First patient enrolment
  • March 2021 - Data freeze for 42 HGSOC patients
  • August 2021 - Preprint reporting major determinants of the HGSOC tumor microenvironment
  • December 2022 - Publication reporting major determinants of the HGSOC tumor microenvironment
Selected Publications
Diseases/Traits Related to Study (MeSH terms)
Links to Related Genes
Authorized Data Access Requests
Study Attribution
  • Principal Investigators
    • Sohrab Shah. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    • Dmitriy Zamarin. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Co-Investigators
    • Ignacio Vázquez-García. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    • Florian Uhlitz. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    • Andrew McPherson. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    • Britta Weigelt. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    • Marc Williams. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Sequencing Center
    • Integrated Genomics Operation. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Funding Sources
    • Cycle for Survival. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    • Collaborative Research Development Grant (648007). Ovarian Cancer Research Alliance, New York, NY, USA.
    • Liz Tilberis Award (657721). Ovarian Cancer Research Alliance, New York, NY, USA.
    • Ann Schreiber Mentored Investigator Award (650687). Ovarian Cancer Research Alliance, New York, NY, USA.
    • W81XWH-20-1-0565. Department of Defense Congressionally Directed Medical Research Programs (CDMRP), Fort Detrick, MD, USA.
    • W81XWH-21-1-0561. Department of Defense Congressionally Directed Medical Research Programs (CDMRP), Fort Detrick, MD, USA.
    • LesLois Shaw Foundation, Etobicoke, ON, Canada.
    • C42358/A27460. Cancer Grand Challenges Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
    • P30-CA008748. National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
    • K99CA256508. National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.